studies

1126A AASLD ABSTRACTS HEPATOLOGY, October, 2015
nificantly affects the long-term natural history of this process
even in low fibrosis groups. Median monitoring intervals of 3
years is suggested to allocate fibrosis and is crucial in non-SVR
& non-Tx patients with F0-F2.
Disclosures:
The following authors have nothing to disclose: Shaul Yaari, Orit Pappo, Saleh
N. Daher, Ariel Benson, Nadav Ilani, Tova Goldberg-Clein, Muhammad Massarwa,
Johnny Amer, Rifaat Safadi
1879
Evaluation of liver and spleen transient elastography in
the diagnosis of esophageal varices
Ayman Alsebaey 1 , Mohamed A. Elmazaly 1 , Maha M. Elsabaawy 1 ,
El-Sayed S. Tharwa 1 , Hanaa M. Badran 1 , Nermine Ehsan 2 , Eman
A. Rewisha 1 ; 1 Hepatology department, National Liver Institute,
Shebin elkom menoufiya, Egypt; 2 Pathology, National Liver Institute,
Shebin Elkoom, Egypt
Background: Portal hypertension with subsequent esophageal
varices (EVs) development is a common complication of HCV
related cirrhosis. Aim: is to evaluate the role of liver stiffness
measurement (LSM), spleen stiffness measurement (SSM) and
their combination (CLSM) using FibroScan TM in diagnosis of
EVs. Methods: One hundred sixty five HCV related F3-4 Metavir
score fibrosis were included. Liver, renal function tests, CBC,
INR and abdominal ultrasonography were done before the
FibroScan TM . Transient elastography measurement was done
using FibroScan TM in the supine position after 6-8 hours fasting
followed by diagnostic esophageogastroscopy. Varices
were classified into none (n= 110), small (n =30) and large (n
=25). Results: Patients with varices had higher serum bilirubin
(1.68±0.82 vs. 1.00±0.55 mg/dl) and lower platelet count
(105.09±31.34vs. 161.21±52.97 ×10 3 /mL) that patients
without varices (p=0.001). The patients with varices had statistically
significant (p=0.001) higher platelets spleen ratio
(671.14±258.89 vs 1215.41±445.58), LSM (31.93±13.29
vs. 17.55±6.53 kPa), SSM (62.85±12.71 vs. 36.94±8.83
kPa) and CLSS (94.78±20.98 vs. 54.49±12.84 kPa) than
patients without varices. In patients with small and large varices
LSM was comparable (30.84±12.69 vs 33.64±13.97 kPa;
p=0.391) but a statistically significant difference was detected
with SSM (59.92±13.47 vs. 66.98±8.67 kPa; p=0.031) and
CLSS (90.76±21.76 vs 100.62±19.00 kPa; p=0.043). With
a cutoff of 20.4 kPa LSM (81.0% sensitivity, 71.8% specificity,
52.3% PPV, 90.8% NPV, 74.3% accuracy), 43.2 kPa SSM
(92.9% sensitivity, 84% specificity, 69.6% PPV, 96.9% NPV,
86.8% accuracy) and 59.3 kPa CLSS (95.2% sensitivity, 70%
specificity, 54.8% PPV, 97.5% NPV, 76.9% accuracy) esophageal
varices can be detected. Conclusion: The measurement of
liver, spleen stiffness by FibroScan TM or their combinations are
useful for esophageal varices diagnosis.
Disclosures:
The following authors have nothing to disclose: Ayman Alsebaey, Mohamed A.
Elmazaly, Maha M. Elsabaawy, El-Sayed S. Tharwa, Hanaa M. Badran, Nermine
Ehsan, Eman A. Rewisha
1880
Self-reported Alcohol Use at Time of HCV Antibody
Screening for Individuals Tested in Community Settings
Michelle Dougherty, Allison Brodsky, Hunana Chaudhry, Carla
Coleman, Lora Magaldi, Carolyn Moy, Ta-Wanda Preston, Stephanie
Tzarnas, Stacey B. Trooskin; Drexel University College of
Medicine, Philadelphia, PA
Background: According to AASLD/IDSA, individuals with HCV
should avoid alcohol. Although there is no safe level of alcohol
consumption, those who consume three or more drinks daily
are at a higher risk for accelerated liver damage. We aim
to assess alcohol use at time of HCV antibody screening for
those tested in community based settings. Methods: A survey
was administered to individuals receiving point of care HCV
testing in community based settings. Data was collected from
June, 2014 to April, 2015. Results: Information about alcohol
consumption was collected from 1,254 individuals who were
tested in community based settings. Of these 1,254 individuals,
11.80% (n=148) tested positive for HCV antibody. 29%
of those who tested positive for HCV antibody reported current
alcohol consumption, compared to 35.7% of individuals who
had no antibody detected. Of the anti-HCV positive individuals
who answered follow up questions regarding alcohol consumption
(n=41), 36.6% reported drinking four or more times per
week, compared to 14.6% of anti-HCV negative individuals
who answered the same follow up questions regarding alcohol
consumption (n=417) [p=0.0003]. Additionally, of the anti-
HCV positive individuals who answered the follow up questions,
17.1% reported consuming seven or more drinks when
they drink, compared to 5.3% of anti-HCV negative individuals
[p=0.0031]. Conclusion: Although individuals who tested
negative for HCV in the community were more likely to report
that they drank alcohol than those who tested positive for antibody
to HCV, the quantity and frequency of alcohol use was
higher among anti-HCV positive individuals. Because alcohol
use is associated with accelerated liver damage, these findings
underscore the need for community outreach, education and
HCV testing programs.
Disclosures:
Michelle Dougherty - Employment: Opening Doors for Diverse Populations to
Health Dispairites Research Under the NIH 1R25MD006792-01 The National
Institute on Minority Health and Health Disparities (NIMHA) Dr. Shannon Marquez,
PI; Grant/Research Support: Gilead Sciences
Allison Brodsky - Grant/Research Support: Gilead
Hunana Chaudhry - Grant/Research Support: Gilead Sciences
Carla Coleman - Grant/Research Support: Gilead Sciences
Lora Magaldi - Grant/Research Support: Gilead Sciences
Carolyn Moy - Grant/Research Support: Gilead
Ta-Wanda Preston - Grant/Research Support: Gilead Sciences
Stephanie Tzarnas - Grant/Research Support: Gilead Sciences
Stacey B. Trooskin - Advisory Committees or Review Panels: Gilead Sciences;
Grant/Research Support: Gilead Sciences
1881
Rate and Predictors of Serum HCV-RNA >6 Million IU/
mL in Chronic Hepatitis C Patients
Pablo Barreiro 2 , Pablo Labarga 1 , Jose V. Fernandez-Montero 4 ,
Carmen de Mendoza 3 , Laura Benitez 3 , Jose M Peña 2 , Vincent
Soriano 2 ; 1 La Luz Clinic, Madrid, Spain; 2 La Paz University Hospital
& IdiPAZ, Madrid, Spain; 3 Internal Medicine, Puerta de Hierro
Research Institute, Majadahonda, Spain; 4 University Hospital
Crosshouse, Kilmarnock, United Kingdom
Background: Baseline serum HCV-RNA predicts sustained
virological response in chronic hepatitis C patients treated
with both peginterferon-ribavirin and more recently with some
direct-acting antiviral regimens. Whereas thresholds around
800,000 IU/mL split out good and poor responders to interferon-based
regimens, a greater threshold at 6,000,000 IU/
mL has been propose to discriminate treatment outcomes on
sofosbuvir-ledipasvir. In comparison with the general population,
immunosuppressed individuals exhibit greater viral load
values. Methods: Serum HCV-RNA values recorded from all
chronic hepatitis C patients consecutively attended at our clinic
during the last decade were analyzed. The COBAS TaqMan
HCV test v2.0 with the high pure system was used, with a